Abstract. 26
Much our understanding of the activity of anthrax toxin is based on in-vitro systems, which 27 delineate the interaction between B. anthracis toxins and the cell surface. These systems 28 however, fail to account for the intimate association of B. anthracis with the circulatory 29 system, including the contribution of serum proteins to the host response and processing of 30 anthrax toxins. Using variety immunologic techniques to inhibit serum processing of B. 31
anthracis Protective Antigen (PA) along with mass spectrometry analysis, we demonstrate 32 that serum digests PA via 2 distinct reactions. In the first reaction, serum cleaves PA83 into 2 33 fragments to produce PA63 and PA20 fragments, similar to that observed following furin 34 digestion. This is followed by carboxypeptidase-mediated removal of the carboxy-terminal 35 arginine and lysine residues from PA20. 36 37 Importance. 38
Our findings identify a serum-mediated modification of PA20 that has not been previously 39 described. These observations further imply that the processing of PA is more complex than 40 currently thought. Additional study is needed to define the contribution of serum processing 41 of PA to the host response and individual susceptibility to anthrax. Bacillus anthracis is the causative agent of anthrax and is widely recognized for its potential 51 use as an agent of bioterrorism. B. anthracis secretes 2 bipartite toxins, lethal and edema 52 toxins that are essential for virulence. Both toxins require the protective antigen (PA) 53 component to mediate cell entry. PA is, therefore, essential to the damaging effects of anthrax 54 toxins and PA-deficient mutants have significantly reduced virulence (1) . 55 56 The current paradigm of toxin pathogenesis posits that B. anthracis secretes the pro-form of 57 PA (PA83), which binds to cell surface receptors (tumor endothelium marker-8 or capillary 58 morphogenesis protein -2 where it undergoes cleavage by cell-associated furin into 2 59 fragments, PA20 and PA63. PA63 subsequently undergoes heptamerization to form a pre-pore 60 structure that binds edema factor (EF) or lethal factor (LF) and is internalized. 61
Understanding the mechanism by which anthrax toxin is processed is important because 62 interference with the processing steps is the basis for the development of therapeutics 63 including furin inhibitors (2). In addition, antibodies reactive to PA are protective in animal 64 models of anthrax and one monoclonal antibody, Raxibacumab, has been licensed for clinical 65 use (3-5). 66
67
Much of our understanding about toxin processing in anthrax pathogenesis is based on 68 experiments using in-vitro systems (Reviewed in (6)). These systems generally do not take 69 into account the role of host serum proteins as part of the host response to anthrax. During 70 the course of anthrax, B. anthracis encounters serum proteins at multiple stages including 71 invasion into the lymphatic system and high-level bacteremia, which occurs in the context of 72 sepsis. In late stages of experimental anthrax in macaques, for example, lethal toxin 73 concentrations on the order of 10 μg/ ml have been reported (7) . The intimate association 74 between B. anthracis and serum is further highlighted by the presence of pathogen-75 associated proteins that directly act on elements within circulation. This includes enzymes 76 that digest host hemoglobin and circulating lethal toxin, which interferes with neutrophil 77 function. (8, 9) . 78 79 Several lines of evidence suggest more complexity to PA processing that is apparent from the 80 current model. Anthrax toxin is released from B. anthracis in vesicles that contain all toxin 81 components (10). Although these vesicles may be rapidly disrupted by serum albumin 82 releasing toxin components (11), they are also released intracellularly. In addition, PA 83 circulating in the serum is found in animal models as a complex of PA63 bound to LF or EF, 84 not as intact PA83 (12). In fact, serum from humans and other species has proteolytic activity 85 that digests PA in a manner similar to furin (13-15). Our previous studies suggest a 86 correlation between, serum-mediated digestion of PA and protection from the killing effects 87 of Lethal Toxin in vitro (15). In the current work, we find that serum-mediated processing 88 of PA is a 2-step reaction that involves carboxypeptidase-mediated truncation of the PA20 89 fragment. 90 91 RESULTS 92 93 Serum-mediated digestion of rPA. Serum treatment of rPA83 produced 2 protein 94 fragments, PA63 and a band that is slightly lower in molecular mass than PA20 ( Figure 1 ; lane 95 6). The larger protein is similar in size to the PA63 produced by furin digestion of rPA83. 96
However the smaller protein is smaller than the PA20 produced by furin digestion of rPA83 97 and is referred to as truncated PA20. Furthermore, serum treatment of rPA83 before or after 98 furin digestion still produced this truncated fragment (Figure 1 , lanes 2 and 4). Heat 99 inactivation of serum prevented this truncation ( Figure 1 ; lanes 3 and 5), consistent with the 100 idea that the enzyme responsible for truncation is heat labile. 101
Inhibition of serum-mediated digestion of rPA.
To determine the precise site at which 102 serum cleaves rPA, we attempted to inhibit serum -mediated cleavage using a library of 103 overlapping peptides, which represent the PA sequence and antibodies that recognize 104 various PA sites. Pre-incubation of rPA with the mAb 19D2, which recognizes an epitope 105 immediately C-terminal of the furin site (16), prevented rPA digestion by serum and furin. 106
This inhibition of digestion was not seen with other PA-specific antibodies, including 7.5 G, 107 which recognizes domain 1 of PA83. Serum-mediated PA cleavage was also prevented by co-108 incubation of serum with 3 overlapping peptides (D5-D7), which contain the furin digestion 109 site, but not with other peptides (including, D12, E1, E2, which represent PA sequences 110 approximately 30 AA residues C terminal to the furin site) (not shown). 111 112 Using chemical inhibitors while measuring PA63 formation, we found that the 113 serine/cysteine protease antipain partially inhibited the formation of PA63. In contrast, none 114 of the other tested protease inhibitors, including bestatin, chymostatin, E-64, leupeptin, 115 pepstatin, phosphoramindon, pefabloc SC and aprotinin prevented PA63 formation. As in 116 previous studies, we found that EDTA was a potent inhibitor of serum mediated digestion of 117 PA83. By contrast, both competitive inhibitors of furin (I and II) prevented serum mediated 118 digestion of PA. For the furin inhibitor I, concentrations as low as 0.001 mg/ml resulted in 119 complete inhibition of serum digestion, whereas for the furin inhibitor II concentrations as 120 low as 0.010 mg/ml produced complete inhibition of digestion ( Figure 2) . 121 122 Truncated PA20 fragment. To better identify the precise site of serum-mediated digestion 123 of rPA, the truncated PA20 fragment produced by serum digestion was examined by mass 124 spectrometry. First the intact protein mass of this fragment was measured and the 125 experimental mass determined by LC-ESI MS to be 23,600 Da ( Figure 1 ). Furin cleaves at 126 RXK/RR, which would correspond to a predicted molecular mass of 25,157 Da for rPA 127 (Figure 3 ; n-terminus to RKKR) a difference of 1,554 Da; way beyond the error of 128 measurement. To determine the sequence of the truncated PA20 fragment in-gel trypsin 129 digestion was performed. The LC-MS/MS data identified the underlined tryptic peptides 130 shown in Figure 3 (identified tryptic peptides of the are listed in supplemental table 1). The 131 peptide sequence, LLNES….GFIK, is too large for fragmentation on the LTQ mass 132 spectrometer and was not detected by MS/MS but the +4, +5, +6, +7 and +8 charge states 133 were detected (Supplemental Figure 2) . The predicted protein mass from the n-terminus to 134 the last tryptic peptide identified is 23,213 Da and if the next 4 amino acids are included 135 (SSNS) the predicted protein mass will increase to 23,588 Da, a difference of 12 Da or 0.05% 136 when compared with the experimental intact protein mass (23,600 Da). These findings are 137 consistent with serum-mediated cleavage of the basic, C-terminal arginine and lysine 138 residues from the PA20 fragment produced by furin digestion followed by possibly 139 carboxypeptidase. 140 141 Carboxypeptidase treatment of rPA. Given these results, we sought to determine whether 142 this truncated PA20 fragment could result from serum carboxypeptidase digestion of PA20. inhibitory activity is not specific to any one class of carboxypeptidases. Addition of GEMSA, 161 (500 g/mL) to serum prevented the formation of a truncated PA20 and resulted in a PA20 162 fragment that was more similar in size to that produced by furin digestion (Figure 5) animal sera contain a furin-like enzyme, which digests PA to produce PA63 and PA20 171 fragments (13) (14) (15) . In our own studies this activity was associated with protection against 172 lethal toxin in vitro (15). We now extend these findings to demonstrate that human serum 173 contains a carboxypeptidase, which further processes the PA20 fragment by removing the C-174 terminal basic amino acid residues, resulting in a truncated PA20 fragment. These findings 175 contrast with the current model of anthrax toxin, which suggests that processing of PA 176 occurs only at the cell surface and provide additional evidence for the complexity of anthrax 177 toxin mechanisms of action. However, we note that serum and cell surface PA processing 178 are not mutually exclusive events. 179 180 PA20 has been detected in the blood of B. anthracis infected animals though its contribution 181 to anthrax pathogenesis is unknown (17). Nonetheless, several lines of evidence suggest may 182 be play an active role in infection. For example, PA20 contains, a PA14 domain that is 183 conserved among bacterial toxins and appears to play a role in cell binding (18). 184 Hammamieh et. al., reported that exposure of human peripheral blood mononuclear cells to 185 PA20 induced a variety of genes related to the inflammatory, cell migration and triggered 186 apoptosis in these cells (17). Furthermore, PA20 has been reported to bind Lethal Factor 187 (19) . Although circumstantial these findings are consistent with a role for PA20 in the 188 pathogenesis of anthrax. Interestingly, both carboxypeptidases inactivate 203 complement anaphylatoxins (27, 28) . Furthermore, both C3 and C5 have been implicated in 204 the host response to anthrax (29, 30) . Thus PA20 may possibly alter anthrax pathogenesis 205 by interfering with anaphylatoxin inactivation during anthrax-associated sepsis. 206 207 It is interesting that CP-N is more susceptible to inhibition by GEMSA, while CPB2 is more 208 susceptible to inhibition by potato carboxypeptidase inhibitor (31). Thus, our findings are 209 consistent with the hypothesis that in vitro, CP-N is primarily responsible for the observed 210 truncation of PA20. Nonetheless, the precise carboxypeptidase responsible for the truncation 211 of PA20 in vivo (including during the sepsis of anthrax) is not known and it is likely that there 212 is redundancy to the process. Of note, macrophages also express a membrane-associated 213 carboxypeptidase (CP-M) that cleaves C-terminal lysines and arginine residues from 214 proteins (32). It is, therefore, likely that a similar processing occurs at the surface of target 215 cells. 216
217
In summary, we demonstrate that serum processing of PA is a 2-step process that involves a 218 furin-like digestion of the PA83 component followed by truncation of the PA20 fragment by 219 serum carboxypeptidases. The significance of these 2 serum-associated activities remains 220 to be defined. Based out earlier studies that associate furin-like digestion with protection, 221
we believe that this activity may in fact contribute to the host response to anthrax. This 222 would be consistent with the close association of B. anthracis to the circulatory system. We 223 also suggest that it is possible that the variation in these serum proteolytic activities 224 contributes to differences in individual susceptibility to anthrax. Additional study looking 225 and gain and lost of function in the context of experimental infection may help further 226 delineate the important of these processes. Antibodies and peptides. A library of 6 murine monoclonal antibodies (7.5G, 16A12, 10F4, 240
19D9, 20G7 and 2H9) that were previously generated and characterized was used to both 241 define the digestion site and as detection reagents for immunoblot studies (33). Binding sites 242 for these antibodies are provided in supplemental table 2. A previously synthesized library 243 of overlapping peptides, which represents the PA sequence, was used for inhibition studies 244 (16). 245
Proteolytic Digestion and Fragment Detection. Proteolytic digestion studies were 246 performed as previously described (15). Briefly, rPA (2.5 μg) was incubated with 25 μl of 247 serum, phosphate buffered saline, or furin (0.5 Units, Invitrogen) at 37°C for 30 -60 minutes. 248
In some experiments, serum was heat-treated at 56 o C for 30 minutes prior to incubation 249 with toxin. In other experiments, protease inhibitors (see below) or peptides at a 250 concentration of 5 μg/ml were added to serum prior to incubation with rPA. Digested rPA 251 was separated by SDS-electrophoresis and transferred to a nitrocellulose membrane. 252
Membranes were blocked with 5% milk and then incubated with primary antibody. The 253 following MAbs were used to characterize rPA cleavage: 10F4 (IgG1) and 7.5G (IgG2b). All 254
MAbs were used at a concentration of 0.25 μg/ml. Primary antibody was detected with 255 horseradish peroxidase-labeled goat isotype-specific antibody at a dilution of 1:25,000. Peptides. Serum (24 μl) was incubated with individual biotinylated peptides, peptide 262 mixtures or PBS for 2 hours at room temperature. These peptides were chosen from a library 263 of peptides representing the entire length of rPA and were synthesized as 15-mer, 264 overlapping by 10 residues (16). This serum peptide mixture was then incubated with 1.5 265 μg of rPA for 30 min at 37 o C and the resulting mixture subjected to separation by SDS page 266 and detection by western blot 267 268 mAbs: PA (1.5 μg) was incubated with one of several PA-specific mAbs (2μg) (33) for 10 269 minutes at room temperature. This mixture was then added to 24 μl of serum, incubated at 270 37 o C for 20 minutes and then subjected to SDS electrophoresis and immunoblotting. 271 272 Protease inhibitors. A volume of 10 μl of sera was pre-incubated with 1 of 9 protease 273 inhibitors included in a commercially available protease inhibitor set (Roche) for 30 minutes 274 at 30 o C.
Individual inhibitors including (antipain, bestatin, chymostatin, E-64, 275 phosphoramidon, pefabloc sc and aprotinin), each of which were reconstituted as per 276 manufacturer's instructions. Following this incubation 1.5 μg of rPA was added to the 277 mixture and incubated at 37 o C for 1 h. Specific inhibition of furin activity was accomplished 278 using Furin inhibitor I (Caymen Chemicals) and Furin inhibitor II (Sigma). These compounds 279 are selective competitive inhibitors of the proprotein convertases, including furin. Serum 280 (12 μl) was incubated with furin inhibitors (at room temperature for 10 minutes and after 281 which rPA (1.5 μg) was added and the entire mixture incubated for an additional 1 h at 37 o C. 282
283
Carboxypeptidase inhibition. For these experiments sera was pre-treated with a variety of 284 inhibitors for 30 minutes prior to incubation with rPA. These inhibitors included: 285 guanidinoethylmercaptosuccinic acid (GEMSA, Santa Cruz Biotechnology), or 286 carboxypeptidase inhibitor from potato tuber extract (Sigma). The serum PA digest mixture 287 was separated by electrophoresis. PA63-like and truncated PA20 fragments were then 288 detected with the antibodies 10F4 and 19D2 respectively. 289 290 Mass spectrometry (MS). To isolate the truncated PA20 molecule, serum-digested rPA was 291 incubated overnight at 4 o C with 200 μl of protein G resin in binding buffer (20 mM Tris, 150 292 mM NaCl, pH 7.4) together with the 50 μg of the mAb 19D2. The resultant slurry was 293 centrifuged for 2.5 min at 2,500 G and the resin washed 5 times with binding buffer (Pierce). 294
Following elution the protein was separated in a non-denaturing gel and electro-eluted for 295 further analysis. 296 297 Mass spectrometric measurements (MS) and liquid chromatographic (LC) separations were 298 obtained on the LTQ linear ion trap mass spectrometer (Thermo Scientific, San Jose, CA), the 299 Rapid Separation LC 3000 (Dionex Corporation, Sunnyvale, CA) for tryptic peptides and the 300 HP 1100 series for intact protein separation. For intact protein molecular weight 301 measurements of the electro-eluted protein a C4 Vydac TP column (1 X 50 mm; 300 Å; 50 302 L/min) was used. After desalting at 1% acetonitrile in 0.1% aqueous formic acid (FA) for 2 303 min the protein was eluted after increasing to 55% acetonitrile in 0.1% aqueous FA. The 304 mass range from 600 to 1800 m/z was acquired on the LTQ and the raw data was 305 deconvoluted using MagTran (34) or ProMass (ThermoFisher Scientific). Another aliquot 306 of the electro-eluted protein was separated on a 1D SDS gel and selected molecular weight 307 bands were excised for in-gel tryptic digestion as described (35). After sample injection and 308 LC peptide separation (using an acetonitrile gradient), the top ten most abundant ions 309 obtained from the survey scan (300 to 1600 m/z) were selected for fragmentation (MS/MS). 310
Normalized collision energy of 35% and a 2 m/z isolation width were used for MS/MS. The 311 MS/MS data were converted to a text file for peptide/protein identification using Mascot 312 (Matrix Science Inc.). 313
314
Carboxypeptidase-mediated digestion of PA. To determine whether, carboxypeptidase 315 digestion of furin treated rPA could produce a fragment similar in size to that seen with 316 serum digestion of rPA, experiments were done with carboxypeptidase B (CPB) (Sigma). For 317 these experiments, rPA was treated with furin for 10 minutes at 30 o C and the mixture was 318 incubated with CPB at different concentrations at 37 o C. Proteins were separated by SDS 319 PAGE and detected by immunoblotting as described above. 
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